Eikon Therapeutics
Update in progressEIKN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Eikon Therapeutics, Inc. is a U.S. clinical biopharmaceutical company focused on medicines for serious unmet medical needs. Its programs include EIK1001, a systemically delivered TLR7/8 dual-agonist to stimulate innate and adaptive anti-tumor immunity; EIK1003 and EIK1004, selective PARP1 inhibitors for ovarian, breast, prostate and pancreatic cancers (EIK1004 is brain-penetrant for brain metastases and primary brain tumors); EIK1005, a WRN helicase inhibitor for MSI-H tumors; and EIK1006, a next-generation AR antagonist targeting resistant AR variants. Founded 2019, based in Millbrae, California.
Company score
- Sentiment
- 0.19
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Roger M. Perlmutter M.D., Ph.D.
- Founded2019
- Employees384
- Websiteeikontx.com
Identifiers
- ISINUS2825641036
- FIGIBBG00T0XRJ75